[go: up one dir, main page]

MX2018009504A - Composiciones y metodos para tratar infecciones. - Google Patents

Composiciones y metodos para tratar infecciones.

Info

Publication number
MX2018009504A
MX2018009504A MX2018009504A MX2018009504A MX2018009504A MX 2018009504 A MX2018009504 A MX 2018009504A MX 2018009504 A MX2018009504 A MX 2018009504A MX 2018009504 A MX2018009504 A MX 2018009504A MX 2018009504 A MX2018009504 A MX 2018009504A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating infections
infections
inhibitors
Prior art date
Application number
MX2018009504A
Other languages
English (en)
Inventor
T Hopper Allen
Thomas Stephen
Welsch Matthew
Original Assignee
Vyera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyera Pharmaceuticals Llc filed Critical Vyera Pharmaceuticals Llc
Publication of MX2018009504A publication Critical patent/MX2018009504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se refiere a inhibidores de dihidrofolato reductasa y preparaciones farmaceuticas de los mismos; la invencion se refiere, ademas, a metodos de tratamiento de infecciones parasitarias, tales como infecciones por T. gondii, T. cruzi, P. falciparum, T. brucei o L. major, usando los inhibidores novedosos de la invencion.
MX2018009504A 2016-02-05 2017-02-02 Composiciones y metodos para tratar infecciones. MX2018009504A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291900P 2016-02-05 2016-02-05
US201662375712P 2016-08-16 2016-08-16
PCT/US2017/016224 WO2017136556A1 (en) 2016-02-05 2017-02-02 Compositions and methods for treating infections

Publications (1)

Publication Number Publication Date
MX2018009504A true MX2018009504A (es) 2019-05-06

Family

ID=59500993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009504A MX2018009504A (es) 2016-02-05 2017-02-02 Composiciones y metodos para tratar infecciones.

Country Status (17)

Country Link
US (2) US10774073B2 (es)
EP (1) EP3411367A4 (es)
JP (1) JP6949055B2 (es)
KR (1) KR20180119590A (es)
CN (1) CN109071486A (es)
AU (2) AU2017213824B9 (es)
BR (1) BR112018015924A2 (es)
CA (1) CA3013760A1 (es)
CL (1) CL2018002074A1 (es)
CU (1) CU20180083A7 (es)
EA (1) EA201891766A1 (es)
IL (2) IL260952B (es)
MX (1) MX2018009504A (es)
PH (1) PH12018501646A1 (es)
SG (2) SG10202007239QA (es)
TW (1) TW201731836A (es)
WO (1) WO2017136556A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891766A1 (ru) * 2016-02-05 2019-02-28 ВИЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Композиции и способы для лечения инфекций
US20200270233A1 (en) * 2017-08-07 2020-08-27 Vyera Pharmaceuticais LLC Dhfr inhibitors, compositions, and methods related thereto
CN109312363B (zh) 2018-04-26 2022-07-15 中科蓝华(广州)生物医药技术有限公司 一种减毒系统及其应用
JP2023539463A (ja) 2020-08-17 2023-09-14 アリゴス セラピューティクス インコーポレイテッド Ｐｄ－ｌ１を標的とするための方法及び組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532240A (en) * 1982-09-09 1985-07-30 Warner-Lambert Company Diaminopyrimidines
JPS5973573A (ja) * 1982-09-09 1984-04-25 ワ−ナ−−ランバ−ト・コンパニ− ジアミノピリミジン化合物
CA1244028A (en) 1983-04-14 1988-11-01 Hans Maag Pyrimidine derivatives
ZA842595B (en) * 1983-04-14 1985-11-27 Hoffmann La Roche Pyrimidine derivatives
AU4690999A (en) 1998-08-13 2000-03-06 Warner-Lambert Company Diaminopyrimidines and combination therapies effective for treatment of p-glycoprotein positive cancers
US20040006042A1 (en) * 1998-08-13 2004-01-08 Berry David Allen Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers
WO2005014573A1 (en) * 2003-08-07 2005-02-17 Pharmacia & Upjohn Company Llc Anthelmintic and insecticide pyrimidine derivatives
EA201891766A1 (ru) 2016-02-05 2019-02-28 ВИЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Композиции и способы для лечения инфекций
US20200270233A1 (en) 2017-08-07 2020-08-27 Vyera Pharmaceuticais LLC Dhfr inhibitors, compositions, and methods related thereto

Also Published As

Publication number Publication date
US10774073B2 (en) 2020-09-15
CN109071486A (zh) 2018-12-21
US11530198B2 (en) 2022-12-20
AU2017213824A1 (en) 2018-09-06
EP3411367A4 (en) 2019-07-10
AU2017213824B9 (en) 2021-11-25
TW201731836A (zh) 2017-09-16
CA3013760A1 (en) 2017-08-10
JP6949055B2 (ja) 2021-10-13
WO2017136556A1 (en) 2017-08-10
EP3411367A1 (en) 2018-12-12
PH12018501646A1 (en) 2019-05-27
JP2019504889A (ja) 2019-02-21
CL2018002074A1 (es) 2019-02-01
US20200407345A1 (en) 2020-12-31
CU20180083A7 (es) 2019-03-04
IL260952B (en) 2022-04-01
BR112018015924A2 (pt) 2018-12-26
AU2022200967A1 (en) 2022-03-03
SG10202007239QA (en) 2020-09-29
AU2017213824B2 (en) 2021-11-18
SG11201806620TA (en) 2018-09-27
IL291266A (en) 2022-05-01
US20190077794A1 (en) 2019-03-14
KR20180119590A (ko) 2018-11-02
EA201891766A1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
ZA202405294B (en) Heterocyclic compounds as immunomodulators
ZA202206806B (en) Benzooxazole derivatives as immunomodulators
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
MY199705A (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2019001125A (es) Inhibidores de cinasa macrociclica.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX383213B (es) Inhibidores de tirosina-cinasas
EA201791095A1 (ru) Способ лечения рака
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
HK1220442A1 (zh) Ido抑制剂
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
GB2541571A (en) Pharmaceutical compositions
EA201790838A1 (ru) Ингибитор киназы aurora a
MX2016000295A (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
EA201890567A1 (ru) Способ лечения рака
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز